Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Drug makers on brink of $65bn patent cliff, says report
Big Pharma
Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.   12 December 2014
Acne drug at centre of ‘first’ IPR ruling of its kind
Americas
Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.   11 December 2014
Europe
Law firm King & Spalding has appointed a partner to its office in Washington, DC.   10 December 2014
Americas
Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.   10 December 2014
Americas
Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).   9 December 2014
Americas
A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.   8 December 2014
Americas
US research centre the Broad Institute of Massachusetts Institute of Technology and Harvard has entered into a worldwide licensing deal with Editas Medicines, granting it access to IP covering genome technology and human therapeutic applications.   5 December 2014
Americas
The US Court of Appeals for the Federal Circuit has overturned a decision on patent claims for a drug used to treat anorexia and cachexia in AIDS patients.   4 December 2014
Americas
Drugs companies Cipla and Meda Pharmaceuticals have sued Canada-based Apotex as they seek to protect the nasal spray Dymista (Azelastine hydrochloride, fluticasone propionate).   3 December 2014
Asia-Pacific
Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.   2 December 2014